Jacobson & Schmitt Advisors LLC boosted its holdings in Danaher Co. (NYSE:DHR – Free Report) by 10.5% during the fourth quarter, Holdings Channel.com reports. The firm owned 88,991 shares of the conglomerate’s stock after acquiring an additional 8,489 shares during the quarter. Danaher comprises about 3.9% of Jacobson & Schmitt Advisors LLC’s portfolio, making the stock its 3rd largest holding. Jacobson & Schmitt Advisors LLC’s holdings in Danaher were worth $20,428,000 as of its most recent filing with the SEC.
Other large investors have also recently made changes to their positions in the company. Cumberland Partners Ltd increased its position in Danaher by 4.8% during the 4th quarter. Cumberland Partners Ltd now owns 15,007 shares of the conglomerate’s stock valued at $3,445,000 after buying an additional 690 shares in the last quarter. Private Wealth Partners LLC grew its stake in shares of Danaher by 4.1% in the fourth quarter. Private Wealth Partners LLC now owns 98,780 shares of the conglomerate’s stock worth $22,675,000 after acquiring an additional 3,912 shares during the last quarter. Private Advisor Group LLC increased its holdings in shares of Danaher by 5.5% during the fourth quarter. Private Advisor Group LLC now owns 48,150 shares of the conglomerate’s stock valued at $11,053,000 after acquiring an additional 2,519 shares in the last quarter. ICICI Prudential Asset Management Co Ltd purchased a new position in shares of Danaher in the 4th quarter worth about $4,591,000. Finally, TKG Advisors LLC boosted its stake in Danaher by 6.9% in the 4th quarter. TKG Advisors LLC now owns 8,421 shares of the conglomerate’s stock worth $2,070,000 after purchasing an additional 547 shares in the last quarter. 79.05% of the stock is currently owned by hedge funds and other institutional investors.
Insiders Place Their Bets
In related news, SVP Brian W. Ellis sold 5,700 shares of the firm’s stock in a transaction that occurred on Thursday, January 30th. The stock was sold at an average price of $224.13, for a total transaction of $1,277,541.00. Following the completion of the sale, the senior vice president now directly owns 20,230 shares of the company’s stock, valued at approximately $4,534,149.90. This trade represents a 21.98 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 10.90% of the stock is owned by insiders.
Wall Street Analysts Forecast Growth
View Our Latest Research Report on Danaher
Danaher Trading Up 0.3 %
Shares of DHR stock opened at $205.23 on Thursday. The company has a market cap of $148.24 billion, a PE ratio of 38.87, a price-to-earnings-growth ratio of 2.63 and a beta of 0.83. Danaher Co. has a 1 year low of $196.80 and a 1 year high of $281.70. The stock’s 50 day simple moving average is $227.74 and its two-hundred day simple moving average is $247.80. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.40 and a quick ratio of 1.05.
Danaher (NYSE:DHR – Get Free Report) last issued its quarterly earnings results on Wednesday, January 29th. The conglomerate reported $2.14 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $2.14. Danaher had a return on equity of 10.82% and a net margin of 16.33%. During the same period in the prior year, the firm earned $2.09 earnings per share. Research analysts predict that Danaher Co. will post 7.67 earnings per share for the current year.
Danaher Announces Dividend
The company also recently disclosed a quarterly dividend, which was paid on Friday, January 31st. Investors of record on Friday, December 27th were given a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a yield of 0.53%. The ex-dividend date of this dividend was Friday, December 27th. Danaher’s dividend payout ratio (DPR) is currently 20.45%.
Danaher Profile
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
Recommended Stories
- Five stocks we like better than Danaher
- P/E Ratio Calculation: How to Assess Stocks
- Nebius Group: NVIDIA’s Investment Sparks All-Time Highs
- When to Sell a Stock for Profit or Loss
- SoFi Stock Rallying Strong in the Last 5 Days—What’s Driving It?
- What is the Nasdaq? Complete Overview with History
- Intel Surges on M&A Talks: Rally Beginning or Just a Headfake?
Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Co. (NYSE:DHR – Free Report).
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.